A trial testing admilparant in IPF succeeded at the lower 60 mg dose, while the higher 120 mg dose failed. And the GEP-NET ...
Brent Saunders exits as Bausch + Lomb CEO by mutual agreement, replaced interim by Thomas Appio. Shares down 3%. Company to ...
Asahi Kasei gets FDA approval for herpes drug Hovilpri for immunocompromised patients, validating its $920M acquisition of ...
Mirum's Livmarli, First Tracks' ANB033, and Tortugas' obuprazine showed positive Phase 3, 1b, and 2b trial results in liver ...
AstraZeneca says an imbalanced adult subgroup sank its Ph3 HICKORY trial of efzimfotase alfa in hypophosphatasia as the FDA ...
PhRMA says FDA will get money it can spend only on hiring and keeping staff, to restore reviewer levels after the HHS layoffs ...
Pancreatic cancer patients with the most common KRAS mutation appeared to have a lower response rate than the overall patient ...
Chan Zuckerberg Biohub launches $1.8B Virtual Biology Initiative with Meta, Google DeepMind, Isomorphic Labs, DOE, and NIH to ...
Ultragenyx sells a rare pediatric disease PRV for $210M, one of 2026's priciest voucher deals, and plans to monetize a second ...
Welcome back to Endpoints Weekly! We unveiled our 2026 Women in Biopharma special project on Monday. Our team pored through nearly 200 nominations to reach this year’s list of 20 ...
The Boston-area biotech hasn’t released any data over the last four weeks, but it still was able to pull off a stock sale ...
IPOs on Nasdaq, backed by Eli Lilly, focusing on Treg science for autoimmune disorders. Pipeline includes TRB-061 and a CD30 agonist for IBD.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results